Elicera Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-17.41	-16.11	-16.4	-19.44	-13.12	Upgrade
Depreciation & Amortization	-	0.01	0.01	0.01	0.01	Upgrade
Other Operating Activities	-	-	0	0	-	Upgrade
Change in Accounts Receivable	-1.41	-	-	-	-	Upgrade
Change in Accounts Payable	0.52	1.16	0.15	-1.32	0.1	Upgrade
Change in Other Net Operating Assets	-3.26	-8.53	1.31	12.17	-1.28	Upgrade
Operating Cash Flow	-21.55	-23.46	-14.92	-8.57	-14.29	Upgrade
Sale (Purchase) of Intangibles	0	-	-0	-	-	Upgrade
Investment in Securities	-	-	0.48	-	-0	Upgrade
Investing Cash Flow	0	-	0.48	-	-0	Upgrade
Issuance of Common Stock	22.03	27.56	-	-	62	Upgrade
Other Financing Activities	-2.03	-7.08	-	-	-6.88	Upgrade
Financing Cash Flow	20	20.48	-	-	55.12	Upgrade
Net Cash Flow	-1.55	-2.98	-14.44	-8.57	40.83	Upgrade
Cash Interest Paid	0.01	0.05	0.08	0.13	0	Upgrade
Cash Income Tax Paid	-	-	-	-0	-	Upgrade
Levered Free Cash Flow	-15.36	-17.94	-9.26	-1.32	-9.37	Upgrade
Unlevered Free Cash Flow	-15.36	-17.91	-9.21	-1.24	-9.37	Upgrade
Change in Working Capital	-4.14	-7.36	1.46	10.85	-1.18	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.